Skip to content

Impact of Noninvasive With Expiratory Washout on Respiratory Rate of Patients With Acute Hypercapnic Respiratory Failure

Evaluate the Impact of Noninvasive (NIV) With Expiratory Washout on Respiratory Rate of Patients With Acute Hypercapnic Respiratory Failure. A Prospective, Randomized Cross Over Pilot Investigation.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05964244
Enrollment
20
Registered
2023-07-27
Start date
2023-11-30
Completion date
2024-05-31
Last updated
2023-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Noninvasive Ventilation

Brief summary

This study will determine if NIV using the Vela investigational mask with expiratory washout of the upper airway more effectively reduces respiratory rate in acute patients with hypercapnic respiratory failure. Patients admitted to hospital with acute respiratory failure (ARF) will be assessed for hypercapnic ARF by normal hospital protocols. Patients requiring noninvasive ventilation (NIV) will be set up on NIV as prescribed per standard of care. Enrollment onto the investigation will occur after the patient has been allowed to stabilize on NIV . Patients that meet the inclusion/exclusion criteria will be approached for consent. Investigation participants will receive two masks in random order; 1. NIV for one hour with the investigational mask (Vela) 2. NIV for one hour with the standard mask (Nivairo). Participants will have their physiological respiratory parameters recorded.

Detailed description

This is a simple study. Patients who are already on noninvasive ventilation (NIV) for acute respiratory failure will be approached for the study within the first 24 hours on NIV therapy. The study will be conducted as described above. After the study patients will be able to choose which mask they continue their NIV on. They will continue NIV as part of their normal hospital care.

Interventions

DEVICEVela Investigational Mask

Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.

DEVICENivairo Standard Mask

Wear mask to enable the delivery of noninvasive ventilation (CPAP or bilevel) therapy.

Sponsors

Fisher and Paykel Healthcare
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

NIV masks can not be masked during the treatments. Only the analysis will be masked.

Intervention model description

Crossover study where each participant receives NIV on the Vela investigational mask and the Nivairo standard mask for one hour each in random order.

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Have type II acute respiratory failure (ARF) and have been prescribed NIV * Arterial blood gas (ABG) Partial pressure of arterial carbon dioxide greater or equal to 6.0 kilopascals (45 millimeters of mercury) * Arterial blood gas acidity greater or equal to 7.35 prior to bilevel commencement * On NIV for 24 hours or less * Negative Covid-19 test * Are 18 years or older

Exclusion criteria

* Contraindicated for NIV * On NIV in Emergency Department/ ward for more than 24 hours, within the last 48 hours * NIV is likely to fail and/or intubation be required, at the doctor's discretion * CPAP or bilevel pressure of 25 centimeters of water or more is required * Unable to tolerate NIV for the duration of the investigation * Do not fit the investigational mask or the standard mask * Pregnancy (tested under standard care) * Agitated * Unable to understand the consent process

Design outcomes

Primary

MeasureTime frameDescription
Change in respiratory rate1 hourThe change in patient's respiratory rate over the 1 hour of the study arm

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026